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Abstract
Purpose—The fracture risk assessment tool (FRAX®) uses clinical factors and bone mineral 
density (BMD) measurement to predict 10-year major osteoporotic (MOF) fracture probability. 
The study aim was to determine whether celiac disease affects MOF risk independent of FRAX 
score.
Methods—The Manitoba BMD Registry includes clinical data, BMD measurements, 10-year 
probability of MOF calculated for each individual using the Canadian FRAX tool and diagnosed 
Ethics approval: This study was approved by the University of Manitoba Research Ethics Board
Consent to Participate: This was a database study and therefore not applicable.
Consent for Publication: This was a database study and therefore not applicable.
Conflict of Interest
Donald Duerksen: Nothing to declare in the context of this paper but has served as a consultant for Takeda and Abbvie.
Lisa Lix: No conflicts of interest.
Helena Johansson: No conflicts of interest.
Eugene McCloskey: Nothing to declare for the context of this paper, but numerous ad hoc consultancies/ speaking honoraria 
and/or research funding from Amgen, Bayer, General Electric, GSK, Hologic, Lilly, Merck Research Labs, Novartis, Novo Nordisk, 
Nycomed, Ono, Pfizer, ProStrakan, Roche, Sanofi-Aventis, Servier, Tethys, UBS and Warner-Chilcott
Nicholas Harvey: Nothing to declare for the context of this paper, but has received consultancy/ lecture fees/ honoraria/ grant funding 
from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare, Radius Health, UCB, Kyowa 
Kirin and Internis Pharma.
John A. Kanis: Nothing to declare in the context of this paper. Has received grants from Amgen, Lilly, Radius Health
William Leslie: No conflicts of interest.
Europe PMC Funders Group
Author Manuscript
Osteoporos Int. Author manuscript; available in PMC 2021 September 03.
Published in final edited form as:









































celiac disease. Using linkage to population-based healthcare databases, we identified incident 
MOF diagnoses over the next 10 years for celiac disease and general population cohorts.
Results—Celiac disease (N=693) was associated with increased fracture risk adjusted for FRAX 
score computed without secondary osteoporosis or BMD (adjusted hazard ratio [HR] 1.43, 95% 
confidence interval [CI] 1.11-1.86). Celiac disease was no longer a significant risk factor for 
fracture when secondary osteoporosis or BMD were included in the FRAX calculation (p>0.1). 
In subjects with celiac disease, each SD increase in FRAX score (calculated with and without 
secondary osteoporosis or BMD) was associated with higher risk of incident MOF (adjusted HR 
1.66 to 1.80), similar to the general population (p-interaction > 0.2). Including celiac disease as 
secondary osteoporosis or including BMD in FRAX 10-year MOF probability calculations (10.1% 
and 8.6% respectively) approximated the observed cumulative 10-year MOF probability (10.8%, 
95 % CI 7.8-13.9%).
Conclusions—Celiac disease is associated with an increased risk of major osteoporotic 
fractures. When celiac disease is considered as a secondary osteoporosis risk factor or BMD 
is included in FRAX assessment, FRAX accurately predicts fracture risk.
Keywords
FRAX score; Major osteoporotic fracture risk; Celiac disease; Osteoporosis; Epidemiology
Introduction
Celiac disease is an autoimmune disorder characterized by small intestinal inflammation 
and villous atrophy upon exposure to gluten in genetically susceptible individuals.1 This 
clinical syndrome of varying manifestations can include gastrointestinal symptoms, extra-
intestinal manifestations and malabsorption of nutrients including calcium and vitamin D. 
There is frequently a significant delay in the initial diagnosis of celiac disease and thus, 
malabsorption may be present for many years prior to definitive treatment.
Individuals with celiac disease (CD) are at increased risk of low bone mineral density 
(BMD) and osteoporosis-related fractures.2 The mechanisms for these effects include 
calcium and vitamin D malabsorption, and chronic inflammation with the secretion of 
pro-inflammatory cytokines.3 A gluten free diet is associated with an improvement in BMD 
as measured by dual-energy X-ray absorptiometry (DXA), although the reported magnitude 
of improvement has varied in the literature.4 Fracture risk, including that for hip fracture, 
appears to be increased in patients with celiac disease although the effect size is uncertain.5
The most widely used approach to patient stratification for fracture risk is the FRAX® 
fracture risk assessment tool, which combines clinical factors that independently predict 
fracture risk as well as (optionally) BMD at the femoral neck to predict 10-year probability 
of major osteoporotic fracture (MOF; a composite of hip, clinical vertebral, forearm and 
humerus fractures) and 10-year probability of hip fracture.6 The FRAX tool was initially 
developed for use in general practice. Since its initial development it has been included 
in over 100 clinical practice guidelines and is the most widely used fracture prediction 
tool worldwide. 7 CD is not a direct input to FRAX. An input for secondary osteoporosis 
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(including malabsorption) is included in the FRAX algorithm which affects the output when 
BMD is not available, but does not affect the risk calculation when BMD is included.
The aim of this study was to determine whether CD affects major osteoporotic fracture risk 
independent of FRAX probability.
Methods
Study Population
Manitoba is a central Canadian province with a population of approximately 1.3 million 
where health care is universal and publicly funded. The provincial healthcare databases 
include diagnoses from physician claims, hospitalizations, pharmacy-dispensed prescription 
medication use, and a provincial CD serology database; all databases can be linked using 
a unique, anonymized personal health identification number. The Manitoba Bone Mineral 
Density (BMD) Database includes all clinical DXA data for the province.8 This database 
has been carefully validated and extensively used for clinical research, with completeness 
and accuracy in excess of 99%.9 The Manitoba BMD Database was linked to the provincial 
databases listed previously.
Individuals were included in the study cohort if they were age 40 or older at the time of 
baseline DXA performed between 1 January 1996 and 30 March 2013 and were registered 
with Manitoba Health. The study protocol was approved by the Faculty of Medicine 
Research Ethics Board (REB) of the University of Manitoba.
Definition of CD
CD was defined as endomysial antibody (EMA) positivity (before 2003) or IgA tissue 
transglutaminase (tTG) and EMA positivity (after 2003) or from administrative healthcare 
data (2 physician claims or 1 hospitalization with a ICD-9-CM 579 or ICD-10-CA K90 
diagnostic code for celiac disease). We have previously demonstrated that the administrative 
case definition for CD has a high sensitivity and specificity when assessed using the 
serologic diagnosis of CD as the reference standard.10 Serologic testing with IgA tTG and 
IgA EMA antibodies has a high sensitivity and specificity for celiac disease for biopsy 
proven celiac disease.1 While small bowel biopsy is recommended for a definitive diagnosis 
in adults, positive serologic testing with tTG and EMA antibodies has a positive predictive 
value of over 95% for biopsy confirmed celiac disease.11 In Manitoba, all serologic testing 
for CD is performed by the Immunology Laboratory at St Boniface Hospital, Winnipeg, 
Canada. Since 1996, IgA endomysial antibody (EMA) testing has been performed using 
fluorescein-conjugated guinea pig IgA antibodies and fluorescence microscopy. Sera are 
considered positive if fluorescence is seen at dilutions of 1:5 or greater. IgA tissue 
transglutaminase (tTG) antibodies have been measured since 2003.
Individuals receiving BMD testing but who did not have positive serologic testing or did not 
meet the administrative case definition for celiac disease were considered the controls for 
this study and designated as members of the general population cohort.
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We defined incident MOF as fractures of the hip, wrist, spine, or humerus that occurred 
between the date of BMD screening and our study end date (March 31, 2013). Fractures 
were ascertained from diagnosis codes in physician claims and hospitalizations using 
previously validated case definitions.12, 13 We excluded fractures associated with trauma 
diagnosis codes. We required a site-specific fracture fixation code and/or casting code for 
hip fracture or humerus fractures. To avoid double-counting health care interactions related 
to the same injury, we only counted a single fracture for a given site within a 180-day period. 
For individuals with more than one incident MOF, we used the first qualifying MOF.
Dual-energy X-ray Absorptiometry (DXA) and FRAX Calculation
DXA scans were performed and analyzed in accordance with manufacturer 
recommendations.9 Hip T-scores were calculated from the NHANES III White female 
reference values. Age- and sex-matched Z-scores were also computed. Prior to 2000, 
DXA measurements were performed with a pencil-beam instrument (DPX, GE Lunar, 
Madison WI) and after this date a fan-beam instrument was used (Prodigy or iDXA, GE 
Lunar, Madison WI). Instruments were cross calibrated using anthropomorphic phantoms 
and volunteers. No clinically significant differences were identified (femoral neck T-score 
differences < 0.1). Therefore, all analyses are based upon the unadjusted numerical results 
provided by the instrument. Densitometers showed stable long-term performance (phantom 
coefficient of variation [CV] < 0.5%) and satisfactory in vivo precision (CV 2.3% for the 
femoral neck).14
Ten-year probability of an MOF was calculated for each subject using the Canadian FRAX 
tool (FRAX® Desktop Multi-Patient Entry, version 3.8). The Canadian FRAX tool was 
calibrated using nationwide hip fracture and mortality data (17). The Manitoba BMD 
Registry was not used in the creation or calibration of the FRAX tool. Weight and height 
were measured at the time of DXA, and body mass index (BMI) was calculated as weight 
(in kilograms) divided by height (in meters) squared. Prior fracture and other FRAX 
input variables were assessed using administrative health data.15 We defined prior fragility 
fracture as any non-traumatic MOF that occurred before the baseline DXA test examining 
medical records back to 1987. Prolonged oral glucocorticoid use (>90 days dispensed in the 
1 year prior to DXA) was obtained from the provincial pharmacy system.16 Parental hip 
fracture was by self-report from 2005 onwards. We adjusted for the effect of incomplete 
parental hip fracture information on FRAX probability estimates before 2005 using age- 
and sex-specific adjustment factors derived from 2005–2008 parental hip fracture responses 
as previously described. 15 Current smoking was by self-report from 2005 onwards and 
from a proxy variable in earlier years (chronic obstructive lung disease diagnosis codes 
in administrative data). High alcohol use from 2012 onwards and from a proxy variable 
in earlier years (alcohol substance abuse diagnosis codes in administrative data). For each 
subject we computed three FRAX MOF probability scores: from clinical predictors only 
(without secondary osteoporosis CD), from clinical predictors with secondary osteoporosis 
(for cohort members with CD), and from clinical predictors including BMD.
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Statistical analyses were performed with Statistica (Version 13.0, StatSoft Inc, Tulsa, OK). 
Descriptive statistics for demographic and baseline characteristics are presented as mean 
± SD for continuous variables or frequency (%) for categorical variables. Analysis of 
variance and χ2 tests of independence were used to test for differences between the CD and 
general population cohorts. Cox proportional hazards semi-parametric regression models 
were used to test the factors associate with time to first fracture, with cohort (CD vs. 
general population) as the covariate of interest. Model covariates included FRAX probability 
calculated from clinical predictors only without secondary osteoporosis for CD (Model 1), 
from clinical predictors with secondary osteoporosis for CD cohort members (Model 2), 
and from clinical predictors including BMD (Model 3). Risk gradients for the fracture 
probability measurements were also estimated for each cohort and are presented as hazard 
ratios (HRs) per SD decrease with 95% confidence intervals (CI). Two-way interaction 
terms (FRAX score * celiac disease) were included in models to test for differences between 
groups. FRAX scores were log-transformed due to a skewed distribution. Sensitivity 
analyses were performed after excluding individuals receiving anti-osteoporosis medication. 
The proportional hazards assumptions was tested and confirmed from the Schoenfeld 
residuals. We also compared cumulative observed fracture incidence to 10-years with FRAX 
score prediction in order to assess calibration (observed vs predicted fracture probability).
Results
The case definition of celiac disease was fulfilled by 693 individuals who were followed 
for a mean of 7.0 years and compared with 68,037 general population subjects followed 
for a mean of 7.1 years (duration of follow-up; p=0.458). Table 1 describes the baseline 
characteristics of the celiac cohort members compared with the general population members. 
The CD cohort tended to be younger, include more males and have lower BMI and femoral 
neck age/sex-adjusted Z-scores (all p<0.001). Despite being younger (p< 0.001) and more 
likely to be male (p<0.001), during follow up 58 (8.4%) members of the CD cohort 
sustained one or more MOF which was similar to the MOF rate experienced by members of 
the general population cohort 5692 (8.4%) (p=0.997).
Table 2 examines the independent effect of celiac disease on major osteoporotic fracture 
risk adjusted for baseline fracture risk using FRAX. FRAX was strongly predictive of 
incident fracture in all models, with an approximate doubling in risk per SD increase. 
Celiac disease was associated with increased fracture risk adjusted for FRAX score 
computed without secondary osteoporosis or BMD (adjusted HR 1.43, 95% CI 1.11-1.86). 
However, celiac disease was no longer a significant risk factor for fracture when secondary 
osteoporosis or bone mineral density inputs were included in the FRAX calculation (p>0.1). 
Anti-osteoporosis medication use did not significantly differ between the groups (12.4% 
in the CD cohort vs 14.8% in the general population cohort, p=0.074). Exclusion of 
treated individuals from the analysis did not affect our results (HR for CD 1.44, 95% CI 
1.08-1.92 adjusted for FRAX score computed without secondary osteoporosis or BMD; 
p>0.1 when secondary osteoporosis or bone mineral density inputs were included in the 
FRAX calculation).
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The performance of FRAX to stratify major osteoporotic fracture risk with and without 
secondary osteoporosis or bone mineral density in the CD cohort and in the general 
population cohort is demonstrated in Table 3. In individuals with CD, each SD increase 
in FRAX score (calculated with or without secondary osteoporosis or BMD) was associated 
with higher risk of incident MOF (adjusted HR 1.66 to 1.80). Similar HRs were noted in 
the general population and in models including two-way interaction terms between FRAX 
probability and cohort (celiac disease vs. general population), the interaction terms were not 
statistically significant (all P>0.2).
Figure 1 compares the observed 10-year major osteoporotic fracture probability with the 
FRAX predicted 10-year major osteoporotic fracture probability in celiac disease and in 
the general population. In the general population, there was good agreement between 
FRAX predicted (11.0% without and 10.6% with BMD) and observed (10.8%) 10-year 
major osteoporotic fracture probability. In celiac disease when secondary osteoporosis and 
BMD were not included in the risk assessment, the observed 10-year major osteoporotic 
fracture probability (10.8%, 95 % CI 7.8-13.9%) was greater than predicted by FRAX 
(7.4%). When celiac disease was considered as secondary osteoporosis, the FRAX major 
osteoporotic fracture probability (10.1%) approximated the observed major osteoporotic 
fracture probability. The predicted probability when BMD was included in the FRAX 
calculation (8.6%) also fell within the 95% CI of the observed probability).
Discussion
The association of celiac disease with abnormal bone mineral density and metabolic bone 
disease has been well established.17 Our study demonstrates that celiac disease is associated 
with an increased risk of major osteoporotic fractures after controlling for multiple clinical 
risk factors. Despite being younger and including a greater proportion of men, the CD 
cohort had the same number of fractures as general population controls. There have been 
conflicting studies regarding the magnitude of increased fracture risk in celiac disease as 
well as the sites that are most at risk. A recent meta-analysis of 9 cross-sectional and case-
control studies demonstrated an overall increased risk of any fracture of 1.91(95%CI 1.29, 
2.84) compared with those without celiac disease and in 6 prospective studies an increased 
risk of any fracture of 1.30 (95% CI 1.14, 1.5).5 For hip fractures, the 4 pooled cross 
sectional and case-control studies did not show an increase risk whereas the 4 prospective 
studies demonstrated an increased risk of 1.69 (95% CI 1.10, 2.59). Our study examined 
major osteoporotic fractures including hip fractures and demonstrated an increased risk of 
major osteoporotic fracture with an adjusted hazard ratio of 1.43 (95% CI 1.11, 1.86).
FRAX is a fracture risk assessment tool that has been validated in many patient populations. 
Our study has demonstrated that FRAX stratifies major osteoporotic fracture risk in the 
celiac disease population similar to the general population with no significant interaction, 
though it does underestimate fracture risk if the independent effect of celiac disease is 
not considered. When celiac disease is included in the FRAX calculation as a secondary 
condition that increases risk for major osteoporotic fractures, it accurately predicts this risk. 
Alternatively, including bone mineral density in the FRAX calculation also predicts that 
fracture risk. The secondary causes mentioned in FRAX are (conservatively) assumed to 
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confer a risk mediated by low BMD.18 The present paper is the first formal demonstration 
that the assumption holds true for malabsorption due to celiac disease.
The Global Longitudinal Study of Osteoporosis in Women (GLOW) evaluated the effect 
of comorbidities on fracture risk in over 50000 women.19 When looking at 2–year fracture 
rates, the age-adjusted hazard ratio for celiac disease was 1.4 (p=0.08). In this cohort, the 
prevalence of celiac disease in women with incident fractures, was 1.1 % in underweight 
women, 0.8% in non obese women and 0.4% in overweight women.20 This cohort relied on 
patient self report for the diagnosis of celiac disease and therefore may have overestimated 
the true prevalence of celiac disease.
There have been several recent reports examining the ability of FRAX to predict 
osteoporotic fracture risk in celiac disease. In a study which utilized US National Health and 
Nutrition Examination (NHANES) data, Kamycheva et al demonstrated that celiac disease 
was an independent risk factor for osteoporotic fractures in men > 40 years of age but not 
in women.21 This study was limited by the low number of tTG defined celiac patients; 
there were only sixteen male and nineteen female serologically positive cases amongst 
the cohort of 5031 patients. Therefore, it is difficult to draw major conclusions from this 
study and likely explains the negative findings in women. A second study applied FRAX 
scoring to 160 newly diagnosed patients with celiac disease who were greater than 40 years 
old.22 While this study suggested that FRAX scoring could be useful to select patients 
who might benefit from a BMD test, it did not test the usefulness of the FRAX score in 
predicting fracture risk in established celiac disease. Similar to the Kamycheva study, this 
study was underpowered to detect a higher facture risk in celiac disease. Italian study that 
screened 7305 patients and looked at risk factors for osteoporosis, found that secondary 
conditions including hyperthyroidism, Crohn’s disease, ulcerative colitis, hypercalciuria and 
celiac disease were osteoporosis risk factors in addition to FRAX, when pooled together.23 
There were only 22 patients with celiac disease in this cohort and therefore the role of celiac 
disease as an independent osteoporosis risk factor is unclear from this study.
Current guidelines on the management of celiac disease do not include the use of FRAX 
in their recommendations. The British Society of Gastroenterology24 as well as the 
European Society for the Study of Celiac Disease25 guidelines recommend routine testing 
of BMD at baseline while the American Society of Gastroenterology guidelines26 have 
no recommendations for BMD testing at diagnosis or follow-up. Our study has validated 
the use of FRAX in celiac disease and future clinical practice guidelines should consider 
incorporation of FRAX estimation in their recommendations.
There are several limitations to this study. Males are underrepresented as the BMD database 
utilized in this study is a referral population with over 90% women. Therefore, the results 
may not apply to men with celiac disease. Dietary patterns including calcium and vitamin D 
intake cannot be assessed from administrative data sources. Similarly, this study could not 
evaluate gluten free diet adherence patterns in patients with celiac disease. Strict adherence 
to a gluten free diet has been associated with improved bone mineral density. Recent studies 
have emphasized that mucosal recovery at 2 years occurs in less than 50% of individuals on 
a gluten free diet,27 an effect that is likely related to gluten ingestion. Therefore, there may 
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be a subgroup of patients with higher MOF risk but this was not evaluated in this study. It is 
possible that including BMD in FRAX predicts MOF better than inclusion of celiac disease 
as a secondary osteoporosis risk factor in individuals who are adherent to a gluten free diet 
but this was not tested in our study. In addition, the celiac disease sample size was relatively 
small. It was of sufficient size to allow for evaluation of overall MOF risk but did not allow 
for analysis of fracture subtypes, most notably hip fractures.
In conclusion, this study demonstrated increased major osteoporotic fracture risk in 
individuals with celiac disease. FRAX is a useful tool to stratify fracture risk in individuals 
with celiac disease. When celiac disease is considered as a secondary osteoporosis risk 
factor or BMD is included in the FRAX assessment, FRAX accurately predicts fracture risk.
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Celiac disease is associated with an increased fracture risk but is not a direct input to the 
FRAX®calculation. When celiac disease is considered as a secondary osteoporosis risk 
factor or BMD is included in the FRAX assessment, FRAX accurately predicts fracture 
risk.
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Figure Legend Observed and predicted 10-year major osteoporotic fracture (MOF) 
probability in celiac disease cohort and general population cohort. Predicted MOF risk uses 
FRAX with clinical risk factors without secondary osteoporosis (CRFs), clinical risk factors 
with secondary osteoporosis (2ary), and with clinical risk factors and bone mineral density 
(BMD). Error bars are 95% confidence intervals.
Obs - Observed
Pred CRFs – predicted from clinical risk factors without secondary osteoporosis
Pred 2ary – predicted from clinical risk factors with celiac disease as secondary osteoporosis
Pred BMD – predicted with clinical risk factors and bone mineral density
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Table 1
Characteristics of General Population and Celiac Disease Cohorts
Characteristic General population Celiac disease p-value
Frequency 68,037 693
Age (years) 64.3 ± 11.2 58.1 ± 11.2 <0.001
Female 61,729 (90.7) 546 (78.8) <0.001
BMI (kg/m2) 27.1 ± 8.2 25.2 ± 5.3 <0.001
Prior fracture 9926 (14.6) 86 (12.4) 0.106
Femoral neck T-score -1.4 ± 1.0 -1.3 ± 1.2 0.484
Femoral neck Z-score 0.0 ± 0.9 -0.3 ± 1.1 <0.001
Femoral neck osteoporotic 8018 (11.8) 99 (14.3) 0.042
FRAX MOF percent (clinical without secondary osteoporosis for celiac disease) 11.0 ± 8.3 7.4 ± 6.5 <0.001
FRAX MOF percent (clinical with secondary osteoporosis for celiac disease) NA 10.1 ± 8.8 <0.001
FRAX MOF percent (with BMD) 10.6 ± 7.8 8.6 ± 8.3 <0.001
Observation time (years) 7.1 ± 4.2 7.0 ± 4.1 0.458
Incident MOF 5692 (8.4) 58 (8.4) 0.997
Data expressed as Mean ± SD or N (percent).
BMI – Body Mass Index
MOF – Major Osteoporotic Fracture
BMD – Bone Mineral Density
NA – Not Applicable
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Table 2
Predictors of Major Osteoporotic Fracture
Hazard Ratio (95% CI) P value
Model 1 Celiac disease (versus absent) 1.43 (1.11-1.86) 0.006
FRAX (clinical without secondary osteoporosis) per SD increase 1.95 (1.89-2.00) <0.001
Model 2 Celiac disease (versus absent) 1.08 (0.84-1.40) 0.542
FRAX (clinical with secondary osteoporosis) per SD increase 1.94 (1.89-2.00) <0.001
Model 3 Celiac disease (versus absent) 1.21 (0.93-1.57) 0.150
FRAX (with BMD) per SD increase 2.09 (2.03-2.14) <0.001
Note: CI = confidence interval
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Table 3
Hazard ratios (HR) with 95% confidence intervals (CI) for incident major osteoporotic 





HR 95% CI Interaction p-value*
FRAX probability from clinical predictors only 1.67 (1.29-2.17) 1.95 (1.89-2.00) 0.238
FRAX probability from clinical predictors with secondary osteoporosis for 
celiac disease
1.66 (1.28-2.16) 1.95 (1.89-2.00) 0.222
FRAX probability from clinical predictors with BMD 1.80 (1.43-2.27) 2.09 (2.03-2.15) 0.209
* FRAX score * celiac disease status.
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